Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.61 -0.73 (-1.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
36 37 Next >
AIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private. 
Via InvestorPlace
Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward. 
Via InvestorPlace
Topics Workforce
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday?
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
(SNY) - Analyzing Sanofi's Short Interest
Via Benzinga
Why the dividend investor may take a look at NASDAQ:SNY.
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. 
Via Chartmill
NASDAQ:SNY is an undervalued gem with solid fundamentals.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential. 
Via InvestorPlace
Passport to Profits: 7 Global Growth Gems to Diversify Your Holdings
With certain sectors in the domestic market appearing overstretched, these global growth stocks may offer better opportunities. 
Via InvestorPlace
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
3 Cash Cow Dividend Stocks for Outsized Income & Upside
With uncertainty again weighing on the market, investors can take shelter under these cash cow dividend stocks. 
Via InvestorPlace
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Move Over Magnificent 7, Say Hello to the GRANOLAS
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
The FDA put studies in eczema and asthma treatment on clinical hold. 
Via Investor's Business Daily
Cruising For A Bruising
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Don't count these companies out too soon. 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
Click here to learn more about CytoReason and how to invest through OurCrowd.  
Via Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. 
Via Benzinga
Sanofi (SNY) Q4 2023 Earnings Call Transcript
SNY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs
Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge. 
Via Benzinga
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
The company missed total sales and earnings expectations. 
Via Investor's Business Daily
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.